A Phase 1 interventional study of Siplizumab in Autoimmune Liver Disease, Liver Transplant Disorder and Autoimmune Hepatitis, sponsored by Elizabeth C. Verna. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by Elizabeth C. Verna · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Hepatitis, Autoimmune with a site in United States — 7 open to participants now, 8 under way, 1 of them phase 3. Hepatitis, Autoimmune · United States.
Among the 21 studies in Hepatitis, Autoimmune with a site in United States, this one is the 11th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 1, and was the 20th registered.
82 studies on the registry are indexed under Hepatitis, Autoimmune; 24 are open to participants now.
Browse Hepatitis, Autoimmune studies →7 of the 21 studies in Hepatitis, Autoimmune with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States, Belgium, Canada and 5 more countries
Ages 18–74
Indiana University · Sites in United States
Ages 18–80
Children's Hospital Medical Center, Cincinnati · Sites in United States
Sanguine Biosciences · Sites in United States
Ages 18–85 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 6–23
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Hepatitis, Autoimmune studies recruiting now, 9 (56%) set no upper age limit and 4 (25%) stop at 75 or younger; 8 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 2
First in 1995; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8 is below the median of 48 across 42 interventional studies indexed under Hepatitis, Autoimmune.
Median enrollment 24 across the 13 interventional studies, 133 across the 8 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 21 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Elizabeth C. Verna as lead sponsor.
Elizabeth C. Verna has 1 study filed under Hepatitis, Autoimmune — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Hepatitis, Autoimmune with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-cluster of differentiation 2 (CD2) monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD. The purpose of this pilot, open-label phase 1 study is to determine the safety of siplizumab for induction in patients with AILD undergoing LT.
Up to eight (8) subjects will receive siplizumab 0.6 mg/kg/dose on the day of transplant (Day 0) and Day 4 post-transplant, for a total of two doses.
All subjects will be followed in the study for 12 months post-LT.
The purpose of this study is to evaluate the safety of siplizumab when used as induction immunosuppression in patients with primary sclerosing cholangitis (PSC) or autoimmune hepatitis (AIH) undergoing liver transplantation. Induction immunosuppression drugs are very potent anti-rejection drugs that are given immediately after transplantation to prevent rejection. Siplizumab is investigational, meaning it has not yet been approved for market use for this disease condition by the United States Food and Drug Administration (FDA).
Adult patients (18 years of age and older) listed for LT with the specific AILD diagnoses of PSC or AIH
All subjects will receive 0.6 mg/kg/dose intravenously on the day of transplant (Day 0) intraoperatively and on post-transplant Day 4.
Participation in this study will last approximately 15 months (\~ 3 months on the LT waitlist, up to 12 months participation post-LT)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
ADDITIONAL exclusion criteria to be reviewed at the time of transplant
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subjects will receive 0.6 mg/kg/dose intravenously on the day of transplant (Day 0) intraoperatively and on post-transplant Day 4.
Drug: Siplizumab
Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD.
Serious infection in the first month post-transplant,
viral, bacterial or fungal infection that leads to readmission, prolonged hospitalization, reoperation, intensive care unit admission, graft loss or death.
Time frame: 1 Month post-transplant
Incidence of immune-mediated liver injury
biopsy proven acute rejection (BPAR), or recurrent AILD
Time frame: 12 month Post-transplant
Incidence of graft loss or death
Loss of liver allograft or incidence of mortality
Time frame: 12 month Post-transplant
Incidence of BPAR
biopsy proven acute rejection within 12 Month post-transplant
Time frame: 12 month Post-transplant
Incidence of treated BPAR
biopsy proven acute rejection that requires treatment within 12 Month post-transplant
Time frame: 12 month Post-transplant
Incidence of refractory BPAR
biopsy proven acute rejection within 12 Month post-transplant that is not responsive to treatment
Time frame: 12 month Post-transplant
Incidence of development of donor specific antibodies (DSA)
Donor specific antibodies within 12 Month Post-transplant
Time frame: 12 month Post-transplant
Incidence of recurrent AILD
based upon histology for autoimmune hepatitis \[AIH\] and histology and/or imaging for primary sclerosing cholangitis \[PSC\]
Time frame: 12 month Post-transplant
Peak plasma concentration (Cmax) after single dose of siplizumab
Cmax after single dose
Time frame: 12 hours Post-treatment
The area under the curve (AUC) from time zero to the last measurable plasma concentration sampling time.
AUC based on plasma concentrations over 84 days post-treatment
Time frame: 84 Days Post-transplant
Descriptive summary statistics by dosing level and visit/sampling time point
the frequency of siplizumab concentrations below the lower-limit of quantification (LLOQ)
Time frame: 12 month Post-transplant
Summary statistics of pharmacokinetic (PK) of Siplizumab
mean, standard deviation (SD), coefficient of variation (CV), median, minimum and maximum of siplizumab concentrations.
Time frame: 12 month Post-transplant
Change in Concentration T-Cells
Change in Concentration of T- cells (cells/uL)
Time frame: 12 month Post treatment
Change in Concentration of B- cells
Change in Concentration of B- cells (cells/uL)
Time frame: 12 month Post treatment
Change in Concentration of NK- cells
Change in Concentration of NK- cells (cells/uL)
Time frame: 12 month Post treatment
CD2 receptor occupancy by dose level and subject
Measurement of CD2 receptor occupancy
Time frame: 12 month Post-transplant
Dynamics of T-cell subset recovery in the blood and allograft liver
Measurement of T-cell subset in the blood and allograft liver
Time frame: 12 month Post-transplant
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Siplizumab